How soon before surgery should Jardiance (Empagliflozin) be discontinued?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Discontinuation of Jardiance (Empagliflozin) Before Surgery

Jardiance (empagliflozin) must be discontinued 3-4 days before surgery to prevent life-threatening euglycemic diabetic ketoacidosis (euDKA). 1, 2

Timing of Discontinuation

  • Stop empagliflozin at least 3 days (≥72 hours) before elective surgery, with some guidelines recommending up to 4 days for certain SGLT2 inhibitors like ertugliflozin. 1, 2, 3

  • The 3-4 day window is necessary because the clinical effects of SGLT2 inhibitors persist beyond their plasma half-life, continuing to promote ketogenesis for several days after the last dose. 3

  • For emergency surgery, the risk of euDKA is significantly higher (1.1% vs 0.17% for elective surgery), requiring heightened vigilance and potentially prophylactic insulin and glucose infusion during the perioperative period. 3, 4

Rationale for Extended Discontinuation

The extended discontinuation period is critical because SGLT2 inhibitors like Jardiance cause euDKA through multiple mechanisms: 3

  • Altered insulin-glucagon ratio that promotes ketogenesis despite normal glucose levels
  • Continued renal glucose excretion leading to relative insulin deficiency
  • Surgical stress and fasting that amplify ketone production

Euglycemic DKA presents with metabolic acidosis (pH <7.3), elevated ketones, and high anion gap despite blood glucose <250 mg/dL (often <14 mmol/L), making it diagnostically challenging. 5, 6, 7

Critical Clinical Pitfalls

  • Even 72+ hours of discontinuation does not guarantee complete protection, as case reports document euDKA occurring 5-7 days after the last dose, particularly in patients with hypovolemia or prolonged fasting. 6

  • Postoperative symptoms of euDKA (nausea, vomiting, tachypnea) are nonspecific and easily attributed to routine postoperative recovery, leading to delayed diagnosis. 5, 8

  • The risk is present in both diabetic and non-diabetic patients taking SGLT2 inhibitors for heart failure, as insufficient insulin reserves cannot prevent ketosis. 3

Risk Mitigation Strategies During Discontinuation

  • Maintain adequate hydration throughout the perioperative period. 2, 3

  • Avoid prolonged fasting periods when possible. 2, 3

  • Consider glucose-containing IV fluids if prolonged fasting is unavoidable to mitigate ketone generation. 2, 3

  • Monitor blood glucose every 2-4 hours while NPO, targeting 100-180 mg/dL perioperatively. 1, 2

  • For emergency surgery when discontinuation is impossible, initiate insulin and glucose infusion at the start of surgery to prevent euDKA. 4

When to Restart Jardiance

  • Do not restart until the patient is clinically stable, eating and drinking normally (typically 24-48 hours postoperatively), and capillary ketones are <0.6 mmol/L. 2, 3

  • Ensure adequate hydration and provide written sick-day rules at discharge. 3

  • For patients with heart failure, recognize that discontinuation may worsen heart failure, requiring careful risk-benefit assessment, though perioperative euDKA prevention takes priority. 2, 3

Special Consideration for Heart Failure Patients

Patients taking Jardiance for heart failure face a clinical dilemma, as cessation may worsen cardiac function. 2, 3 However, the risk of life-threatening euDKA, which can trigger acute coronary syndrome and cardiac arrest (as documented in post-CABG patients), outweighs the temporary discontinuation risk. 7

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.